Purilogics (DCI)

Executive Summary

Purilogics, a subsidiary of Donaldson Life Science, is a leader in membrane chromatography technology for downstream bioprocessing. Its core product, the Purexa™ membrane platform, enables rapid, single-use purification with fast cycle times and consistent performance, addressing critical bottlenecks in biologics manufacturing. The technology offers significant advantages over traditional resin-based chromatography, including higher throughput, lower operating costs, and scalability from lab to commercial production. As the biopharmaceutical industry increasingly adopts continuous processing and single-use systems, Purilogics is well-positioned to capture market share. The company's integration within Donaldson provides access to extensive distribution, manufacturing capabilities, and financial stability, supporting continued R&D and global expansion. The market for membrane chromatography is projected to grow at a double-digit CAGR, driven by the rising demand for monoclonal antibodies, gene therapies, and vaccines. Purilogics' technology differentiates through high binding capacity and robustness, making it suitable for challenging purifications. Recent investments in capacity expansion and development of next-gen membranes are expected to fuel growth. However, competition from established players like Sartorius, Merck, and Cytiva remains intense. Key risks include slower-than-expected adoption of membrane chromatography and regulatory hurdles for client products. Overall, Purilogics leverages a proven technology platform and strong parent support to capitalize on industry trends toward efficiency and flexibility in bioprocessing.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation Purexa™ membrane with enhanced capacity80% success
• TBDMajor pharmaceutical partnership for use in commercial biologic manufacturing60% success
• TBDRegulatory approval of a client's therapy using Purexa™ technology50% success